Equities

Shield Therapeutics PLC

STX:LSE

Shield Therapeutics PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)9.60
  • Today's Change-0.40 / -4.00%
  • Shares traded1.94m
  • 1 Year change209.68%
  • Beta2.7196
Data delayed at least 20 minutes, as of Feb 06 2026 16:01 GMT.
More ▼

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Shield Therapeutics PLC grew revenues 145.93% from 13.09m to 32.18m. Additionally the company has reduced the cost of goods sold, selling, general and administrative expenses and debt expenses (all as percentages of sales). These changes narrowed profitability losses from -33.29m to -27.18m.
Gross margin48.34%
Net profit margin-51.18%
Operating margin-35.20%
Return on assets-39.02%
Return on equity--
Return on investment-131.46%
More ▼

Cash flow in USDView more

In 2024, cash reserves at Shield Therapeutics PLC fell by 7.42m. Cash Flow from Financing totalled 1.43m or 4.43% of revenues. In addition the company used 6.77m for operations while cash used for investing totalled 2.16m.
Cash flow per share-0.0162
Price/Cash flow per share--
Book value per share-0.0106
Tangible book value per share-0.0244
More ▼

Balance sheet in USDView more

Shield Therapeutics PLC has a Debt to Total Capital ratio of 221.87%, a lower figure than the previous year's 3,637.52%.
Current ratio0.8271
Quick ratio0.6922
Total debt/total equity--
Total debt/total capital2.22
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.